Telesta Therapeutics
Formerly called | Bioniche Life Sciences Inc. |
---|---|
Public | |
Traded as | TSX: TST (formerly TSX: BNC) |
Industry | pharmaceutical |
Key people | Michael Berendt (CEO, CSO) |
Telesta Therapeutics Inc. is a publicly traded, Canadian pharmaceutical company based in Montreal, Quebec.[1] CEO Michael Berendt; prior to joining Telesta, was the president and CEO of Aegera Therapeutics.[2]
As part of the strategic push to focus on late stage human therapeutics, effective May 2014, the company divested its Animal Health unit to Vétoquinol, a family-owned, global animal health company led by CEO Matthieu Frechin.[3]
In 2014, a court decision involving a group of Bioniche shareholders and the Bioniche board of directors established a precedent in the Canadian court system for conditions under which a board may choose not to select the date proposed by shareholders for an Annual Meeting, but rather schedule on a date of the board's choosing, thus confirming "that directors have wide latitude to manage corporate affairs."[4]
Telesta is listed on the Toronto Stock Exchange under the symbol TST.[1] Prior to the name change for the company, trading was done under the symbol BNC.[5]
As of December 2014, the strategic focus of Telesta was on the commercialization of "Mycobacterium phlei cell-wall - nucleic acid complex" (MCNA) for the treatment of bladder cancer.[6] The company pursued but did not secure orphan drug status via the United States Food and Drug Administration.[7]
References
- ↑ 1.0 1.1 "Company Information". Stock Market Quotes. TMX Group.
- ↑ Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Pharma. Med Ad News. p. 27.
- ↑ Staff (1 April 2014). "Vétoquinol Acquires Animal Health Business of Bioniche Life Sciences". DVM Newsmagazine (Advanstar) – via Highbeam Research.
- ↑ White, Guy (26 April 2014). "Proactive Business Judgment in Proxy Contests". Mondaq Business Briefing (Mondaq) – via Highbeam Research.
- ↑ "Bioniche". Telesta. Retrieved 24 January 2015.
The Company is publicly traded on the Toronto Stock Exchange and, effective on Monday, December 1st, its ticker will change to TSX:TST from TSX.BNC.
- ↑ Staff (14 December 2014). "Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc". Health & Medicine Week (NewsRx) – via Highbeam Research.
- ↑ Staff (19 November 2014). "Orphan Drug Designation Update and Annual General Meeting Reminder". Biotech Week – via Highbeam Research.